Fredrik Lehmann

Directeur/Membre du Conseil chez GUARD THERAPEUTICS INTERNATIONAL AB

Profil

Fredrik Lehmann is currently Chief Executive Officer & Director at OT Pharmaceuticals AB, Chief Executive Officer at Zalvac AB, Chairman at Synartro AB, Independent Director at Sprint Bioscience AB since 2019, Independent Director at Guard Therapeutics International AB since 2022, Director at Immuneed AB, Director at AnaCardio AB, Director at Teitur Trophics ApS, Director at AnaCardio Holding AB, and Venture Partner at Industrifonden since 2022.
Former positions include CEO at OnTarget Chemistry AB from 2009 to 2016, Chief Executive Officer at EpiEndo Pharmaceuticals ehf, Director at OT Lehmann Holding AB, CMC Director at Axelar AB from 2011 to 2012, Director at Akinion Pharmaceuticals AB, Head-Research, Chemistry, Manufacturing & Control at Oncopeptides AB from 2018 to 2022, and General Manager at Ofichem Uppsala AB. Education includes an MBA from Stockholm School of Economics in 2021, a graduate degree from the University of Uppsala in 2000, and a doctorate from the University of Gothenburg in 2007.

Postes actifs de Fredrik Lehmann

Sociétés	Poste	Début
GUARD THERAPEUTICS INTERNATIONAL AB	Directeur/Membre du Conseil	01/12/2022
SPRINT BIOSCIENCE AB	Directeur/Membre du Conseil	01/01/2019
Industrifonden	Private Equity Investor	01/10/2022
Teitur Trophics ApS	Directeur/Membre du Conseil	-
AnaCardio AB	Directeur/Membre du Conseil	-
Immuneed AB	Directeur/Membre du Conseil	-
OT Pharmaceuticals AB	Directeur Général	-
Synartro AB	Président	-
AnaCardio Holding AB	Directeur/Membre du Conseil	-

Anciens postes connus de Fredrik Lehmann

Sociétés	Poste	Fin
░░░░░░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░ ░░░░░░░ ░░░░░░░ ░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░